<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357292</url>
  </required_header>
  <id_info>
    <org_study_id>LT1225-PI1-09/01(AS)</org_study_id>
    <nct_id>NCT00357292</nct_id>
  </id_info>
  <brief_title>Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers</brief_title>
  <official_title>Comparison of the Ocular Tolerance, the Safety and the Ocular Pharmacokinetics After One Drop of Three Different Concentrations of T1225 (0.5% - 1.0% - 1.5%) in 48 Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <brief_summary>
    <textblock>
      To compare the ocular tolerance, the safety and the ocular pharmacokinetics of 3&#xD;
      concentrations (0.5% - 1.0% - 1.5%) and the vehicle of T1225 after one drop instillation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present study was to compare the ocular tolerance, safety and the ocular&#xD;
      pharmacokinetics after a single administration of T1225 eye drops (0.5%, 1.0%, or 1.5%) in&#xD;
      healthy volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date>April 2002</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular subjective symptoms</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Ocular objective symptoms</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular pharmacokinetic.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular and systemic adverse events.</measure>
  </secondary_outcome>
  <condition>Eye Infections, Bacterial</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin (T1225)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged from 18 to 45 years old;&#xD;
&#xD;
          -  Written informed consent;&#xD;
&#xD;
          -  Healthy volunteers (without any ocular symptom);&#xD;
&#xD;
          -  Normal ocular examination in both eyes (corrected visual acuity (VA) &gt;= 6/10 - Slit&#xD;
             lamp examination without clinical relevant abnormalities - Tear break-up time (BUT)&#xD;
             â‰¥10 seconds - Lachrymal secretion in the Schirmer test &gt;= 10 mm in 5 minutes -&#xD;
             Lissamine green test total score &lt; 4 +).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular trauma, infection or inflammation within the last 3 months;&#xD;
&#xD;
          -  Blepharitis;&#xD;
&#xD;
          -  Conjunctival hyperaemia (score &gt;= 2 +);&#xD;
&#xD;
          -  Watering (score &gt;= 2);&#xD;
&#xD;
          -  Contact lenses;&#xD;
&#xD;
          -  Ocular surgery, including LASIK and PRK, within the last 12 months;&#xD;
&#xD;
          -  Topical ocular treatment within the last month;&#xD;
&#xD;
          -  Systemic antibiotics within the last 7 days;&#xD;
&#xD;
          -  Any medication during the study (except: Paracetamol and contraceptives).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khalid TABBARA, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Eye Center, Riyadh (Saudi Arabia)</affiliation>
  </overall_official>
  <verification_date>July 2006</verification_date>
  <study_first_submitted>July 25, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <last_update_submitted>July 26, 2006</last_update_submitted>
  <last_update_submitted_qc>July 26, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Eye Infections</mesh_term>
    <mesh_term>Eye Infections, Bacterial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

